REUSER et al. USSN 09/886,477

U.S.C. §132. Accordingly, entry of the amendments prior to examination of the application is respectfully requested.

Respectfully submitted,

NATH & ASSOCIATES PLLC

Date:

L)

T)

(1)

m

M

Movember 15,2001

NATH & ASSOCIATES PLLC

1030 Fifteenth Street, N.W.

Sixth Floor

Washington, D.C. 20005-1503

Telephone: (202) 775-8383

Facsimile: (202) 775-8396

GMN:TLJ:JBG:\prelim.doc

Gary M. Nat

Reg. No. 26,965 Joshua B. Goldberg

Reg. No. 44,126

Customer No. 20529

[] 4. ĮQ.

(I) M

4,1

4,

**:** il mi p p a

-

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of

Arnold J. REUSER et al.

Serial No.: 09/886,477

Filing Date: June 22, 2001

METHODS OF PURIFYING HUMAN ACID ALPHA-GLUCOSIDASE For:

## Appendix A

Please cancel presently pending claims 38-39 and amend the following claims as indicated in the following marked up copy of the claims.

- 3. (Once Amended) The method of claim 2 [or claim 3], wherein the anion exchange column is Q-Ssepharose.
- (Once Amended) The method of claim [4] 3, wherein the sample is applied to the Q-Sepharose column in low salt buffer and is eluted from the column in an elution buffer of higher salt concentration.
- 5. (Once Amended) The method of claim 2 [or claim 3], wherein the anion exchange column is copper chelating Sepharose.
- (Once Amended) The method of claim 2 [or claim 3], 7. wherein the hydrophobic interaction column is phenyl Sepharose.
- (Once Amended) The method of claim 2 [or claim 3], wherein the hydrophobic interaction column is Source Phenyl 15.
- 10. (Once Amended) The method of [any one of claims] claim 2 [to 9], further comprising repeating steps (a) and (b) and/or

- (c) until the a-glucosidase has been purified to 95%, preferably 99%, more preferably 99.9% w/w pure.
- 11. (Once Amended) The method of [any one of claims] claim
  2 [to 10], wherein the sample is milk produced by a transgenic
  mammal expressing the a-glucosidase in its milk.
- 14. (Once Amended) The method of [any one of claims] <u>claim</u>
  11 [to 13], further comprising centrifuging the milk and removing fat leaving skimmed milk.
- 18. (Once Amended) The method of [any preceding] claim  $\underline{1}$ , wherein the sample has a volume of at least 100 liters.
- 22. (Once Amended) At least 95%, preferably at least 99%, more preferably at least 99.9% w/w pure human [Human] acid aglucosidase [of any one of claims 19-21] produced by the process of [any one of claims 1-18] claim 1.
- 24. (Once Amended) A pharmaceutical composition comprising human acid a-glucosidase as claimed in [any one of claims 19-21] claim 19.
- 25. (Once Amended) Human acid a glucosidase of [any one of claims 19-21] claim 19 for use as a pharmaceutical.
- 27. (Once Amended) The use of human acid a-glucosidase of [any one of claims 19-21] claim 19 for the manufacture of a medicament for treatment of human acid a-glucosidase deficiency.
- 28. (Once Amended) The use of human acid a-glucosidase of [any one of claims 19-21] claim 19 for the manufacture of a medicament for intravenous administration for the treatment of human acid a-glucosidase deficiency.
  - 32. (Once Amended) A method as claimed in [any of claims]

claim 29 [to 31] being a batch procedure.

- 33. (Once Amended) A method as claimed in [any of claims] claim 29 [to 31], wherein the hydroxylapatite is in the form of a column, optionally the method is a liquid column chromatography procedure.
- 34. (Once Amended) A method as claimed in [any of claims] claim 29 [to 33], wherein the heterologous protein [ie] is selected from the group consisting of [lactoferrin, transferrin, lactalbumin, factor IX, growth hormone, a-anti-trypsin,] lactoferrin, transferrin, lactalbumin, coaqulation factors such as factor VIII and factor IX, growth hormone, a-anti-trypsin, plasma proteins such as serum albumin, C1-esterase inhibitor and fibrinogen, collagen, immunoglobulins, tissue plasminogen activator, interferons, interleukins, peptide hormones, and proteins such as a-glucosidase, a-L-iduronidase, lysosomal iduronate-sulfate sulfatase, hexosaminidase A and B, ganglioside activator protein, arylsulfatase A and B, iduronate sulfatase, heparan N-sulfatase, galactoceramidase, a-galactosylceramidase sphingomyelinase, a-fucosidase, a-mannosidase, Α, aspartylglycosamine amide hydrolase, acid lipase, N-acetyl-a-Dglycosamine-6-sulphate sulfatase, a-and ss-galactosidase, ssglucuronidase, ss-mannosidase, ceramidase, galactocerebrosidase, a-N-acetylgalactosaminidase, and protective protein and others including allelic, cognate or induced variants as well as polypeptide fragments of the same.
- 35. (Once Amended) A method as claimed in [any of claims] claim 29 [to 24], wherein the heterologous protein is not one

normally found in the milk of an animal.

37. (Once Amended) The method of claim [26] 36, wherein the hydroxylapatite is in the form of a column and the unbound fraction is collected in the flow-through.